|
WO2021053582A1
|
|
All-in-one self inactivating crispr vectors
|
|
WO2021044378A1
|
|
Genetically engineered t cells having improved persistence in culture
|
|
US2021070835A1
|
|
Universal donor cells
|
|
US2021071201A1
|
|
Universal donor cells
|
|
US2020405761A1
|
|
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
WO2020264254A1
|
|
Materials and methods for controlling gene editing
|
|
WO2020261219A1
|
|
Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
|
|
WO2020254872A2
|
|
Methods and compositions for improved homology directed repair
|
|
WO2020225606A1
|
|
Crispr/cas all-in-two vector systems for treatment of dmd
|
|
WO2020222176A1
|
|
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
US2020384125A1
|
|
Gene editing for hemophilia a with improved factor viii expression
|
|
WO2020168362A1
|
|
Gene editing for hemophilia a with improved factor viii expression
|
|
WO2020186059A2
|
|
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
|
WO2020209959A1
|
|
Nucleobase-editing fusion protein systems, compositions, and uses thereof
|
|
WO2020112908A2
|
|
OPTIMIZED mRNA ENCODING CAS9 FOR USE IN LNPs
|
|
WO2020095248A1
|
|
Anti-ptk7 immune cell cancer therapy
|
|
WO2020095107A1
|
|
Anti-cd33 immune cell cancer therapy
|
|
WO2020095249A1
|
|
Anti-liv1 immune cell cancer therapy
|
|
US2020080114A1
|
|
Universal donor cells
|
|
AU2019293286A1
|
|
Compositions and methods for genomic editing by insertion of donor polynucleotides
|
